De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Genomic Valley Biotech Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Yogesh Agrawal

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	1.3yrs
Eigendom CEO	53.2%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	less than a year

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Yogesh Agrawal's beloning veranderd ten opzichte van Genomic Valley Biotech's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	₹2m
Jun 30 2024	n/a	n/a	₹1m
Mar 31 2024	n/a	n/a	₹152k
Dec 31 2023	n/a	n/a	₹11m
Sep 30 2023	n/a	n/a	₹2m
Jun 30 2023	n/a	n/a	₹2m
Mar 31 2023	₹600k	₹600k	₹6m
Dec 31 2022	n/a	n/a	-₹2m
Sep 30 2022	n/a	n/a	₹7m
Jun 30 2022	n/a	n/a	₹6m
Mar 31 2022	₹550k	₹550k	-₹93k
Dec 31 2021	n/a	n/a	-₹5m
Sep 30 2021	n/a	n/a	-₹6m
Jun 30 2021	n/a	n/a	-₹5m
Mar 31 2021	n/a	n/a	-₹6m
Dec 31 2020	n/a	n/a	-₹155k
Sep 30 2020	n/a	n/a	₹909k
Jun 30 2020	n/a	n/a	₹1m
Mar 31 2020	₹450k	₹450k	₹3m
Dec 31 2019	n/a	n/a	₹3m
Sep 30 2019	n/a	n/a	₹2m
Jun 30 2019	n/a	n/a	₹2m
Mar 31 2019	₹900k	₹900k	₹2m
Dec 31 2018	n/a	n/a	₹1m
Sep 30 2018	n/a	n/a	₹448k
Jun 30 2018	n/a	n/a	₹380k
Mar 31 2018	₹2m	₹2m	₹341k

Compensatie versus markt: Er zijn onvoldoende gegevens om vast te stellen of de totale vergoeding van Yogesh redelijk is in vergelijking met bedrijven van vergelijkbare omvang in de Indian markt.

Compensatie versus inkomsten: De vergoeding van Yogesh is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Yogesh Agrawal (60 yo)

1.3yrs

Tenure

₹600,000

Compensatie

Mr. Yogesh Agrawal serves as Managing Director and Chairman at Genomic Valley Biotech Ltd and has been its Director since March 15, 1996 and served as its Compliance Officer and Company Secretary since May...

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Yogesh Agrawal	MD, Chairman & CFO	28.6yrs	₹600.00k	53.25% ₹ 159.5m
Parul Agrawal	Additional Non-Independent & Non-Executive Director	less than a year	geen gegevens	2.8% ₹ 8.4m
Ashok Kumar	Additional Non-Executive & Non-Independent Director	less than a year	geen gegevens	geen gegevens

0.9yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van 539206 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.9 jaar), wat duidt op een nieuw bestuur.

Genomic Valley Biotech Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Board Member recently sold ₹3.1m worth of stock

Board Member recently sold ₹2.7m worth of stock

Genomic Valley Biotech Limited Announces Appointment of Mrs. Parul Agrawal as an Additional Non-Executive (Non-Independent) Director on the Board with Effect from February 14, 2024

Genomic Valley Biotech Limited Announces Resignation of Mrs. Jyoti Bansal as Non-Executive (Independent) Director of the Company Effective December 14, 2023

Genomic Valley Biotech Limited Announces Resignation of Parul Agrawal as Non-Executive (Non-Independent) Director and Reconstitution of Committees

Genomic Valley Biotech Limited, Annual General Meeting, Sep 30, 2023

Recent updates

Board Member recently sold ₹3.1m worth of stock

Second quarter 2025 earnings released: EPS: ₹0.48 (vs ₹0.08 in 2Q 2024)

Genomic Valley Biotech Limited to Report Q2, 2025 Results on Oct 07, 2024

Board Member recently sold ₹2.7m worth of stock

First quarter 2025 earnings released: EPS: ₹0.42 (vs ₹0.09 in 1Q 2024)

Genomic Valley Biotech Limited to Report Q1, 2025 Results on Jul 29, 2024

Genomic Valley Biotech Limited to Report Q4, 2024 Results on May 09, 2024

Investor sentiment deteriorates as stock falls 19%

Now 22% undervalued after recent price drop

Now 23% undervalued

Now 21% undervalued

Third quarter 2024 earnings released: EPS: ₹0.07 (vs ₹2.79 loss in 3Q 2023)

Genomic Valley Biotech Limited Announces Appointment of Mrs. Parul Agrawal as an Additional Non-Executive (Non-Independent) Director on the Board with Effect from February 14, 2024

Investor sentiment deteriorates as stock falls 16%

Investor sentiment improves as stock rises 16%

Genomic Valley Biotech Limited Announces Resignation of Mrs. Jyoti Bansal as Non-Executive (Independent) Director of the Company Effective December 14, 2023

Investor sentiment improves as stock rises 15%

Second quarter 2024 earnings released: EPS: ₹0.08 (vs ₹0.20 in 2Q 2023)

Genomic Valley Biotech Limited Announces Resignation of Parul Agrawal as Non-Executive (Non-Independent) Director and Reconstitution of Committees

Genomic Valley Biotech Limited to Report Q2, 2024 Results on Nov 08, 2023

Genomic Valley Biotech Limited, Annual General Meeting, Sep 30, 2023

New minor risk - Profit margin trend

First quarter 2024 earnings released: EPS: ₹0.09 (vs ₹1.50 in 1Q 2023)

Genomic Valley Biotech Limited to Report Q1, 2024 Results on Aug 14, 2023

Genomic Valley Biotech Limited Appoints Yogesh Agrawal as Chief Financial Officer

Third quarter 2023 earnings released: ₹2.79 loss per share (vs ₹0.04 profit in 3Q 2022)

Genomic Valley Biotech Limited Announces Appointment of Mr. Pritam as Company Secretary and Compliance Officer

Genomic Valley Biotech Limited to Report Q3, 2023 Results on Feb 14, 2023

Genomic Valley Biotech Limited, Annual General Meeting, Dec 30, 2022

Second quarter 2023 earnings released: EPS: ₹0.20 (vs ₹0.19 loss in 2Q 2022)

Genomic Valley Biotech Limited to Report Q2, 2023 Results on Nov 12, 2022

Genomic Valley Biotech Limited to Report Q1, 2023 Results on Jul 20, 2022

Genomic Valley Biotech Limited Announces Resignation of Hanurnan Prasad as Company Secretary and Compliance Officer

Full year 2022 earnings released: ₹0.03 loss per share (vs ₹1.83 loss in FY 2021)

Genomic Valley Biotech Limited to Report Q4, 2022 Results on May 28, 2022